Exchange: NASDAQ·Updated 07:30 PM EDT

IRWD News

News
all
press releases
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
Zacks
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
Zacks
More News
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Zacks
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Zacks
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast of Ironwoods fireside chat will be accessible through the Investors...
Business Wire
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
Zacks
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +19.23% and -5.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. Throughout the first half of...
Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646...
Business Wire
Community Health Q2 Loss Wider Than Expected, 2026 View Lowered
CYH posts a wider-than-expected Q2 loss as revenues fall and the company cuts its 2026 revenue, EBITDA and earnings outlook.
Zacks

Advertisement|Remove ads.